IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Otsuki, et al.

App. No : 10/785,446

Filed: February 23,2004

For : METHOD OF TREATMENT OF

DISEASE USING AN ADENOSINE A1

RECEPTOR ANTAGONIST

Examiner : Royds, Leslie A.

Art Unit : 1614

Conf # : 1443

RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement mailed February 11, 2008, Applicants provisionally elect to prosecute claims to Group II, (Claims 10-13 and 26-34), drawn to methods of treating a cardiovascular disease with an adenosine A₁ receptor antagonist. Applicants also elect heart failure as a species of cardiovascular disease, KW-3902 as a species of AA₁RA, and carvedilol as a species of beta blocker. Claims that read on this species include Claims 10-13 and 26-32 and 34.

Amendments to the Claims are reflected in the Listing of the Claims, which begins on page 2 of this paper.

Remarks/Arguments begin on page 10 of this paper.